Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Payables (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Payables for 4 consecutive years, with $2.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 0.73% to $2.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.6 million, a 0.73% increase, with the full-year FY2024 number at $3.1 million, up 12.19% from a year prior.
  • Payables was $2.6 million for Q3 2025 at Century Therapeutics, down from $3.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $9.9 million in Q1 2022 to a low of $2.6 million in Q3 2024.
  • A 4-year average of $4.2 million and a median of $3.5 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: plummeted 64.87% in 2023, then rose 12.19% in 2024.
  • Century Therapeutics' Payables stood at $5.5 million in 2022, then tumbled by 49.74% to $2.7 million in 2023, then rose by 12.19% to $3.1 million in 2024, then fell by 14.89% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Payables are $2.6 million (Q3 2025), $3.2 million (Q2 2025), and $3.6 million (Q1 2025).